1 |
World Health Organization. Guidelines for treatment of tuberculosis, fourth edition. Geneva, Switzerland; World Health Organization, 2010.
|
2 |
Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704
DOI
|
3 |
Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention, 2020 March. p16-59.
|
4 |
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427
DOI
|
5 |
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. https://doi.org/10.1056/NEJM200104263441706
DOI
|
6 |
World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: emergency update 2008. Geneva, Switzerland; World Health Organization, 2008.
|
7 |
David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20:810-814. https://doi.org/10.1128/aem.20.5.810-814.1970
DOI
|
8 |
Bloch AB, Cauthen GM, Onorato IM, Dansbury KG, Kelly GD, Driver CR, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671. https://doi.org/10.1001/jama.271.9.665
DOI
|
9 |
Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet. 2009;373:1861-1873. https://doi.org/10.1016/S0140-6736(09)60331-7
DOI
|
10 |
Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med. 2010;363:1050-1058. https://doi.org/10.1056/NEJMra0908076
DOI
|
11 |
Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007;11:571-576.
|
12 |
Meacci F, Orru G, Iona E, Giannoni F, Piersimoni C, Pozzi G, et al. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol. 2005;43: 3114-3120. https://doi.org/10.1128/jcm.43.7.3114-3120.2005
DOI
|
13 |
Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 1st ed. Seoul; Korea Centers for Disease Control and Prevention, 2011:34-36.
|
14 |
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of anti-tuberculosis therapy. Am J Respir Crit Care Med. 2006;174: 935-952. https://doi.org/10.1164/rccm.200510-1666st
DOI
|
15 |
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7:249-259. https://doi.org/10.1016/s2213-2600(18)30426-0
DOI
|
16 |
Singh J, Garg PK, Tandon RK. Hepatotoxicity due to anti-tuberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol. 1996;22:211-214. https://doi.org/10.1097/00004836-199604000-00012
DOI
|
17 |
Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002
DOI
|
18 |
Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. https://doi.org/10.1056/NEJM199806043382301
DOI
|
19 |
Oh SH, Kim YJ, Park SK, Hwang SH, Kim HH, Lee EY, et al. Comparison of anti-mycobacterial drug susceptibility test results by institutes and methods. Korean J Clin Microbiol. 2008;11: 43-48. https://doi.org/10.5145/kjcm.2008.11.1.43
DOI
|
20 |
Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh YS, et al. Comparison of effectiveness and adverse reactions between isoniazid 300 mg and 400 mg in korean patients with pulmonary tuberculosis. Tuberc Respir Dis. 2006;60:44-48. https://doi.org/10.4046/trd.2006.60.1.44
DOI
|
21 |
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320-1330.
|
22 |
Joint Committee for the Development of Korean Guidelines for Tuberculosis. Korean guidelines for tuberculosis. 4th ed. Seoul; Korea Centers for Disease Control and Prevention, 2020 May. p13-15.
|
23 |
Kim JY, Park YJ, Lee NY, Chang CL, Lee MA, Shin JH. Anti-tuberculosis drug resistant rates in Mycobacterium tuberculosis isolated from respiratory specimens: A multicenter study in Korea. Ann Clin Microbiol. 2013;16:1-7. https://doi.org/10.5145/acm.2013.16.1.1
DOI
|
24 |
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380:1201-1213. https://doi.org/10.1056/NEJMoa1811867
DOI
|
25 |
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5:291-360. https://doi.org/10.1016/S2213-2600(17)30079-6
DOI
|
26 |
Chang KC, Nuermberger E, Sotgiu G, Leung CC. New drugs and regimens for tuberculosis. Respirology. 2018;23:978-990. https://doi.org/10.1111/resp.13345
DOI
|
27 |
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167: 603-662. https://doi.org/10.1164/rccm.167.4.603
DOI
|